Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in France with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Phase: Not applicable Country / region: France Clear all

13 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20071
20101
20121
20142
20192
20202
20231
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting2
Unknown status2
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris1
CHU de Reims1
Centre Hospitalier Régional Metz-Thionville1
Centre Hospitalier Universitaire de Nice1
European Organisation for Research and Treatment of Cancer - EORTC1
ISIS Diabete Service1
Institut National de la Santé Et de la Recherche Médicale, France1
Institut Paoli-Calmettes1
Nantes University Hospital1
Rennes University Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma13
Leukemia, Myeloid, Acute3
Agnosia1
Anxiety Disorders1
Blast Crisis1
Burkitt Lymphoma1
Congenital Abnormalities1
Diabetes Mellitus, Type 11
Fever1
Hepatic Veno-Occlusive Disease1

Trials

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.